bioRxiv Preprint Server
June 12, 2022
Luciana López-Jury, Francisco García-Rosales, Eugenia González-Palomares et al.
preprint
Although new advances in neuroscience allow the study of vocal communication in awake animals, substantial progress in the processing of vocalizations has been made from brains of anaesthetized preparations. Thus, understanding how anaesthetics affect neuronal responses is of paramount importance. Here, we used electrophysiological recordings and computational modelling to study how the...
Journal of Neurochemistry
June 9, 2022
Vern Lewis, Brandon Rodrigue, Emma J. Arsenault et al.
Ketamine has shown antidepressant effects in patients with major depressive disorder (MDD) resistant to first‐line treatments and approved for use in this patient population. Ketamine induces several forms of synaptic plasticity, which are proposed to underlie its antidepressant effects. However, the molecular mechanism of action directly responsible for ketamine's antidepressant effects...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
June 8, 2022
Weam W Ibrahim, R. H. Sayed, Esraa A Kandil et al.
Dysregulated inflammatory responses and blood-brain barrier (BBB) dysfunction are recognized as central factors in the development of psychiatric disorders. The present study was designed to evaluate the effect of niacin on BBB integrity in ketamine-induced model of psychosis. Meanwhile, mepenzolate bromide (MPN), a GPR109A receptor blocker, was used to investigate the role of this receptor on...
European Psychiatry
June 1, 2022
M. Barbosa, R. Guedes
IntroductionEsketamine is an S-enantiomer of ketamine approved by the EMA for treatment-resistant depression (TRD). As an NMDA receptor antagonist, its administration results in increase of glutamate release and AMPA receptor activation, supporting both rapid-onset and long-term antidepressant effects. Short-term tolerability seems acceptable but major concerns remain regarding long-term...
Fundamental and Clinical Pharmacology
June 2022
Jules Baudot, Thomas Soeiro, Marine Tambon et al.
Prominent features of esketamine (e.g., similar mechanism of action as ketamine and target population) require to be vigilant regarding its benefits/risks balance and its risks of abuse in real-life settings. The aim of this study was to review all available pharmacological and clinical data to assess the abuse potential of esketamine shortly after its marketing. This multidimensional study is...
Neuroscience & Biobehavioral Reviews
June 1, 2022
Xingming Wang, Jianjun Yang, Kenji Hashimoto
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. The increasing social and economic burdens of neurological disorders are driven by global population growth and aging. Depression is a common psychiatric symptom in numerous neurological disorders. It is also a risk factor for Alzheimer's disease (AD) and other dementias, Parkinson's...
Behavioural Pharmacology
June 1, 2022
José Eduardo Suárez-Santiago, Gabriel Roldán Roldán, Ofir Picazo Picazo
Schizophrenia is a serious mental disorder that affects 1% of the world’s population. Although various therapeutic tools have been developed since the appearance of the first generation of antipsychotics, the effect of these agents does not manage to attenuate a significant part of psychotic symptoms. Ketamine is an anesthetic agent able to produce psychotic-like symptoms through the antagonism...
Biological Psychiatry
June 1, 2022
Yukitoshi Izumi, F. Hsu, C. Conway et al.
BACKGROUND: Nitrous oxide (N2O) is a non-competitive inhibitor of NMDA receptors (NMDARs) that appears to have ketamine-like rapid antidepressant effects in patients with treatment resistant major depression. In preclinical studies, ketamine enhances glutamate-mediated synaptic transmission in hippocampus and prefrontal cortex. The present study examined effects of N2O on glutamate transmission...
Anesthesia & Analgesia
June 1, 2022
Michael A. Brito, Duan Li, Christopher W Fields et al.
Neurophysiologic complexity has been shown to decrease during states characterized by a depressed level of consciousness, such as sleep or anesthesia. Conversely, neurophysiologic complexity is increased during exposure to serotonergic psychedelics or subanesthetic doses of dissociative anesthetics. However, the neurochemical substrates underlying changes in neurophysiologic complexity are...
European Psychiatry
June 1, 2022
D. Khalifa, L. Rashed, A. Shamseldeen et al.
Introduction Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that combining ketamine with isolation could result in long-lasting neuro-psychological deficits and schizophrenia-like features; thus, it could probably be used as the first model...